Full Title
A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid LeukemiaPurpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Aaron Goldberg’s office at 646-608-3752.
Protocol
25-283
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
ClinicalTrials.gov ID
NCT06235801